Information Hub

Clinical News

2020-01-22

FDA approved trastuzumab deruxtecan for HER2-positive breast cancer

Trastuzumab deruxtecan received FDA approval for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received ≥2 prior anti–HER2-based regimens in the metastatic setting.

Source:

Modi S. et al. N Engl J Med. 2019

2020-01-22

Veliparib plus carboplatin and paclitaxel showed clinically meaningful benefit in HER2 negative breast cancer patients with BRCA mutation

A combination of veliparib, carboplatin, and paclitaxel significantly improve the PFS of breast cancer patients who had low HER2 expression and a BRCA mutation in phase 3 BROCADE3 study.

Source:

Annals of Oncology (2019)

2020-01-22

Tucatinib triplet reduces risk of death in metastatic HER2-positive breast cancer

HER2-positive breast cancer patients have limited treatment options after therapy with multiple HER2-targeted agents. In the HER2CLIMB trial, the addition of tucatinib to trastuzumab and capecitabine showed clinicl benefit in heavily pretreated HER2-posit

Source:

N Engl J Med. 2019

2019-12-30

A new targeted therapy for advanced gastrointestinal stromal tumors (GIST)

Ripretinib is a novel tyrosine kinase inhibitor that was designed to target KIT and PDGFRα-mutated kinase. A phase III study (INVICTUS) showed that ripretinib improved PFS and OS compared with placebo in patients with GIST progressed with more than three

Source:

2019 ESMO congress

2019-12-30

Maintenance olaparib with bevacizumab improves progression-free Survival in patients with newly diagnosed ovarian cancer

In phase 3 PAOLA-1 trial, olaparib plus bevacizumab as first-line maintenance therapy significantly prolongs the progression-free survival of ovarian cancer patients.

Source:

N Engl J Med & Annals of Oncology

2019-12-30

Neratinib ± fulvestrant was effective in patients with advanced breast cancer and HER2 mutations

The plasmaMATCH trial is a phase 2a, open-label, multicentre trial in patients with advanced breast cancer. The trial aims to evaluate whether certain genetic mutation identified through ctDNA could benefit patients from matched targeted treatments. In th

Source:

Wardley. SABCS 2019

2019-11-27

Co-occurring PIK3CA mutations in cis increase PI3K/AKT/mTOR signaling pathway activation and sensitivity to PI3Kα inhibitors in breast cancer

A study showed the mechanism of activating PI3K/AKT/mTOR signaling by double PIK3CA mutations in cis. Furthermore, a retrospective analysis of a phase III study (SANDPIPER) showed that co-occurring PIK3CA mutations were associated with clinical benefits i

Source:

Science. 2019

2019-11-27

Ivosidenib significantly improved the survival of cholangiocarcinoma patients who had a mutation in IDH1

In phase 3 ClarIDHy trial, ivosidenib showed a strong efficacy in treating cholangiocarcinoma patients who had an IDH1 mutation. Ivosidenib extended both the OS and PFS significantly compared to the control group.

Source:

Annals of Oncology (2019)

2019-11-27

Cabozantinib prolonged PFS and improved ORR compared to sunitinib among renal cell carcinoma patients, especially in those with MET alteration

There is ongoing debate on which treatment is optimal for patients with advanced renal cell carcinoma. The phase II CABOSUN trial demonstrated cabozantinib improved response compared to sunitinib. The MET status was associated with greater benefit.

Source:

Oncologist. 2019

2019-10-24

Olaparib showed clinical benefits in heavily pretreated mCRPC with homologous recombination repair (HRR) gene mutations

A phase III study (PROfound) showed that homologous recombination repair (HRR) gene mutations were associated with greater clinical benefits compared with physician’s choice of enzalutamide or abiraterone plus prednisone in heavily pretreated mCRPC patien

Source:

ESMO Congress 2019